Cost effectiveness and cost utility of the noncoding blood glucose meter CONTOUR® TS
Przemyslaw Holko, Pawal KawalecHTA Centre, Kraków, PolandAims: This study assessed the cost efficacy and cost utility of the automatic blood glucose meter CONTOUR® TS from the public payer (National Health Fund [NHF]) and payer (patient and NHF) perspectives over a 26-year...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2011-02-01
|
| Series: | Diabetes, Metabolic Syndrome and Obesity |
| Online Access: | http://www.dovepress.com/cost-effectiveness-and-cost-utility-of-the-noncoding-blood-glucose-met-a6293 |
| _version_ | 1811173838841446400 |
|---|---|
| author | Przemyslaw Holko Pawal Kawalec |
| author_facet | Przemyslaw Holko Pawal Kawalec |
| author_sort | Przemyslaw Holko |
| collection | DOAJ |
| description | Przemyslaw Holko, Pawal KawalecHTA Centre, Kraków, PolandAims: This study assessed the cost efficacy and cost utility of the automatic blood glucose meter CONTOUR® TS from the public payer (National Health Fund [NHF]) and payer (patient and NHF) perspectives over a 26-year analysis horizon.Methods: Clinical effectiveness data were obtained from prior clinical studies of automatic versus manually coded blood glucose meters. Cost data were obtained from the NHF. The probability of procedure use related to diabetic complications was obtained from four medical centers in Poland. The incremental cost-effectiveness ratio related to 1 life year gained and the incremental cost-utility ratio related to 1 quality-adjusted life year gained were calculated.Results: Assuming co-funding from public funds, introduction of the CONTOUR® TS is associated with savings of Polish złoty (PLN) 31,846.19 (€8916.93) and PLN 113,018.19 (€31,645.09) per life year gained from the payer and public payer perspectives, respectively. Cost utility analyses showed that the CONTOUR® TS is associated with savings of PLN 40,465.59 (€11,330.37) and PLN 11,434.82 (€3201.75) per quality-adjusted life year gained from the payer and the public payer perspectives, respectively.Conclusion: The CONTOUR® TS appears superior to manually coded meters available in Poland both from the payer and the public payer perspectives and may represent an improved strategy for glycemic control.Keywords: blood glucose self monitoring, costs and cost analysis, health care costs, diabetes mellitus, diabetes complications  |
| first_indexed | 2024-04-10T17:54:38Z |
| format | Article |
| id | doaj.art-f89ebbbb2d884ad4a2f677dfe89c6847 |
| institution | Directory Open Access Journal |
| issn | 1178-7007 |
| language | English |
| last_indexed | 2024-04-10T17:54:38Z |
| publishDate | 2011-02-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Diabetes, Metabolic Syndrome and Obesity |
| spelling | doaj.art-f89ebbbb2d884ad4a2f677dfe89c68472023-02-02T19:35:36ZengDove Medical PressDiabetes, Metabolic Syndrome and Obesity1178-70072011-02-012011default7988Cost effectiveness and cost utility of the noncoding blood glucose meter CONTOUR® TSPrzemyslaw HolkoPawal KawalecPrzemyslaw Holko, Pawal KawalecHTA Centre, Kraków, PolandAims: This study assessed the cost efficacy and cost utility of the automatic blood glucose meter CONTOUR® TS from the public payer (National Health Fund [NHF]) and payer (patient and NHF) perspectives over a 26-year analysis horizon.Methods: Clinical effectiveness data were obtained from prior clinical studies of automatic versus manually coded blood glucose meters. Cost data were obtained from the NHF. The probability of procedure use related to diabetic complications was obtained from four medical centers in Poland. The incremental cost-effectiveness ratio related to 1 life year gained and the incremental cost-utility ratio related to 1 quality-adjusted life year gained were calculated.Results: Assuming co-funding from public funds, introduction of the CONTOUR® TS is associated with savings of Polish złoty (PLN) 31,846.19 (€8916.93) and PLN 113,018.19 (€31,645.09) per life year gained from the payer and public payer perspectives, respectively. Cost utility analyses showed that the CONTOUR® TS is associated with savings of PLN 40,465.59 (€11,330.37) and PLN 11,434.82 (€3201.75) per quality-adjusted life year gained from the payer and the public payer perspectives, respectively.Conclusion: The CONTOUR® TS appears superior to manually coded meters available in Poland both from the payer and the public payer perspectives and may represent an improved strategy for glycemic control.Keywords: blood glucose self monitoring, costs and cost analysis, health care costs, diabetes mellitus, diabetes complications http://www.dovepress.com/cost-effectiveness-and-cost-utility-of-the-noncoding-blood-glucose-met-a6293 |
| spellingShingle | Przemyslaw Holko Pawal Kawalec Cost effectiveness and cost utility of the noncoding blood glucose meter CONTOUR® TS Diabetes, Metabolic Syndrome and Obesity |
| title | Cost effectiveness and cost utility of the noncoding blood glucose meter CONTOUR® TS |
| title_full | Cost effectiveness and cost utility of the noncoding blood glucose meter CONTOUR® TS |
| title_fullStr | Cost effectiveness and cost utility of the noncoding blood glucose meter CONTOUR® TS |
| title_full_unstemmed | Cost effectiveness and cost utility of the noncoding blood glucose meter CONTOUR® TS |
| title_short | Cost effectiveness and cost utility of the noncoding blood glucose meter CONTOUR® TS |
| title_sort | cost effectiveness and cost utility of the noncoding blood glucose meter contour amp reg ts |
| url | http://www.dovepress.com/cost-effectiveness-and-cost-utility-of-the-noncoding-blood-glucose-met-a6293 |
| work_keys_str_mv | AT przemyslawholko costeffectivenessandcostutilityofthenoncodingbloodglucosemetercontourampregts AT pawalkawalec costeffectivenessandcostutilityofthenoncodingbloodglucosemetercontourampregts |